Product Description

Tirzepatide improves glycemic control by activating GLP-1 and GIP receptors. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in glycemic control. GLP-1, the main effect is to suppress appetite by adjusting pancreatic chemicalbook insulin secretion, delaying gastric emptying. GIP gastric inhibitory peptide, mainly by inhibiting gastric acid secretion and gastric motility, also has a certain effect on protecting pancreatic islets and adjusting insulin secretion. So, to put it simply, after this medicine enters the human body, it has a double appetite suppression effect.